PGI2 prevents ischemia-induced alterations in cardiac catecholamines without influencing nerve-stimulation-induced catecholamine release in nonischemic conditions.
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001783:Blood Flow Velocity; D001794:Blood Pressure; D002395:Catecholamines / Q000378:metabolism*; D003327:Coronary Disease / Q000378:metabolism* / Q000503:physiopathology; D003402:Creatine Kinase / Q000378:metabolism; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D006321:Heart / Q000502:physiology*; D006334:Heart Function Tests; D006651:Histocytochemistry; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010101:Oxygen Consumption; D011453:Prostaglandins / Q000494:pharmacology*; D011817:Rabbits
D002395:Catecholamines; D011453:Prostaglandins; D000255:Adenosine Triphosphate; D011464:Epoprostenol; D003402:Creatine Kinase